| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Lymphangioma is still a difficult disease to obtain satisfactory results. Surgical resection or sclerotherapy is the first choice for treatment. OK-432 and bleomycin have been used for sclerotherapy, and rapamycin for systemic therapy. OK-432 is well known to be one of the first line drugs for sclerotherapy, although it is not available in every country. Some cases are very effective to use OK-432. Although mechanism of action is unclear.
We established a method to obtain primary culture of human lymphangioma derived lymphatic endothelial cell (HL-LEC) from surgically resected tissue. It became a very good material for studying lymphangioma. The purpose of this study is to understand mechanism of several drug’s ,especially OK432’s, direct action against lymphangioma using HL-LEC in a condition without immune reaction. HL-LEC incorporates OK-432 and then dies. OK-432 particle remained after cell death. Microarray analysis showed OK-432 induced apoptosis for HL-LEC.
|
